Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks

February 27, 2023
Pfizer Japan has gone ahead with its plan to put a stop to the shipments of its antidepressant Amoxan (amoxapine) and introduce a recall of the product, as it announced previously following the detection of potentially cancer-causing impurities in the...read more